Early clinical results from Abbott's ongoing ABSORB clinical trial, the world's first study to evaluate the safety and performance of a fully bioabsorbable drug-eluting stent platform for the treatment of coronary artery disease in humans, were presented during the 18th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C.

ev3 Inc. has announced a worldwide fracture-free guarantee in support of its new EverFlex family of stents. In the event ...

Boston Scientific Corporation announced that an independent meta-analysis of more than 3,500 patients from five clinical ...

Obesity and the illnesses associated with it cost the U.S. some 90.7 billion dollars a year in health care costs, a University of Pennsylvania researcher said. Among developed countries, the U.S. has the most obese and overweight people, representing 66 percent of its overall population.

Radiofrequency ablation is more effective than treatment with amiodarone for the prevention of atrial flutter recurrence in patients who experienced a first symptomatic episode, according to the results of a new study. In addition to the superiority of ablation over amiodarone, there was no increased risk of atrial fibrillation, even in this cohort of older patients, report investigators.

When it comes to opening blocked carotid arteries, surgery may be less risky than stents according to a study by French doctors including Jean-Louis Mas, M.D., of the Hospitaux Sainte-Anne in Paris.

Boston Scientific has European CE clearance to begin marketing a private-label XIENCE V everolimus-eluting coronary ...

The new Fetch Aspiration Catheter from Possis Medical, Inc. has received 510(k) clearance from the FDA. Employing ...